You are here


Found 64 results
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is B. Haibe-Kains  [Clear All Filters]
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nature Medecine. 2010.
Juul N, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans FW, Desmedt C, et al. Evaluation of an RNA interference screen-derived mitotic and ceramide pathway meta- gene in paclitaxel-treated primary ER-/PR-/ERBB2- breast cancer: a retrospective analysis of five clinical trials. Lancet Oncology. 2010.
Haibe-Kains B, Desmedt C, Rothé F, Piccart M, Sotiriou C, Bontempi G. A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biology. 2010.
Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, et al. Long term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010.
Lamoral-Theys D, Le Mercier M, Le Calvé B, Rynkowski MA, Bruyère C, Decaestecker C, Haibe-Kains B, Bontempi G, Dubois J, Lefranc F, et al. Long-term Temozolomide Treatment Induces Marked Amino Metabolism Modifications and an Increase in TMZ Sensitivity in Hs683 Oligodendroglioma Cells. Neoplasia. 2010.
Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, et al. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS ONE. 2010.
Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans FW, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor positive breast cancer. PNAS. 2010.
Haibe-Kains B, Culhane AC, Desmedt C, Bontempi G, Quackenbush J, Sotiriou C. Robustness of breast cancer molecular subtypes identification. Annals of Oncology. 2010.
Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart MJ, Phillips WA, McArthur GA, et al. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. J Clin Oncol (Meeting Abstracts). 2009:533-.
Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, et al. Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia. 2009:485–496.
Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, Smeets A, Lallemand F, Haibe-Kains B, Viale G, Gelber R, et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Medical Genomics. 2009:40.
Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Soree A, De Bruyn C, Hanosset D, Bron D, Martiat P, Lagneaux L, et al. Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica. 2009:790-799.
Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, et al. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. J Clin Oncol. 2009:3185-3191.
Haibe-Kains B. Identification and Assessment of Gene Signatures in Human Breast Cancer.
Toussaint J, Sieuwerts A, Haibe-Kains B, Desmedt C, Rouas G, Harris A, Larsimont D, Piccart M, Foekens J, Durbecq V, et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009:424.
Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009:5237-5245.
Ravoet M, Sibille C, Gu C, Libin M, Haibe-Kains B, Sotiriou C, Goldman M, Roufosse F, Willard-Gallo K. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood. 2009:blood-2008-08-175091.
Lefranc F, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Kiss R. Temozolomide displays antimigratory effects in human glioblastoma cells mediated through neuregulin-1 down-regulation. Surgical Neurology. 2009:134 - 134.


Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer